Aug 2026· Korean Journal of Family Medicine· 0 citations· 31 references
Medicine
TL;DR
The association between serum Hcy levels and mortality differed across liver fibrosis strata, and stricter Hcy thresholds are warranted in populations with a higher risk of liver fibrosis.
Abstract
Background
Elevated serum homocysteine (Hcy) levels have been associated with increased mortality; however, whether this association varies with the liver fibrosis burden remains unclear.
Methods
We analyzed 16,541 adults from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2006 with mortality follow-up through December 31, 2019, via the National Death Index linkage. Serum Hcy levels were categorized as <10, 10-15, or >15 μmol/L. Liver fibrosis was assessed using the fibrosis-4 (FIB-4) index. Cox proportional hazard regression models, accounting for the complex survey design, were used to estimate the associations.
Results
During a mean follow-up of 182.4 months, 3,740 deaths occurred. Hcy >15 μmol/L was associated with increased all-cause mortality regardless of liver fibrosis status. In contrast, moderate elevations (10-15 μmol/L) were associated with higher mortality only among participants with a higher FIB-4 index (hazard ratio [HR], 1.30; 95% confidence interval [CI], 1.19-1.42), but not among those with a lower FIB-4 index (HR, 1.24; 95% CI, 0.92-1.67). Kaplan-Meier curves showed greater separation across Hcy categories in the high FIB-4 group. Natural cubic spline analyses demonstrated nonlinear associations between Hcy and mortality that differed according to fibrosis status. Cause-specific analyses indicated that these associations were primarily driven by metabolic and other nonmalignant deaths, rather than malignant mortality. The findings were consistent across fibrosis quartiles, subgroup analyses, and sensitivity analyses.
Conclusion
The association between serum Hcy levels and mortality differed across liver fibrosis strata. These findings suggest that stricter Hcy thresholds are warranted in populations with a higher risk of liver fibrosis.
Cancer incidence was modestly higher at elevated serum vitamin B12 concentrations but attenuated after exclusion of early events, whereas the mortality association at deficiency-range concentrations persisted.
Yuan-Tsung Tseng, Kow-Tong Chen, Pei-Chen Lee et al.· Journal of NutriLife· 0 citations
Mortality was lowest at hemoglobin concentrations 1 to 3 g/dL above current WHO thresholds, with higher mortality below and above this range, with higher mortality below and above this range.
Malek Ahmad, J. G. Cleland, P. Maffia et al.· Annals of Internal Medicine· 0 citations
Low serum vitamin B12 was associated with higher all-cause mortality; its association with CRC was less robust at longer landmarks; the CRC finding requires prospective confirmation with serial B12 measurements.
Yuan-Tsung Tseng, Kow-Tong Chen, Pei-Chen Lee et al.· Cancer Epidemiology, Biomark...· 0 citations
Objective To investigate the association between baseline total cholesterol (TC) levels and incident heart failure (HF) risk in patients with atherosclerotic cardiovascular disease (ASCVD). Methods This retrospective cohort analysis was based on the Kailuan Study, a prospective cohort initiated in Tangshan, China. A to...
Xiao-Xiao Wang, Shou-Lin Wu, Hai-Bo Gao et al.· Frontiers in Medicine· 0 citations
ObjectiveCoronary heart disease (CHD) constitutes a primary cause of morbidity and mortality worldwide. The estimated glucose disposal rate (eGDR) serves as a surrogate marker of insulin resistance, whereas the albumin-bilirubin (ALBI) score reflects liver-related systemic status. However, their joint associations with...
Y. Lei, Guang Li, Qiu-Yue Huang et al.· Science in progress· 0 citations
Aim
. To evaluate the associations of anemia with various cardiovascular disease (CVD) risk factors, comorbidity, and mortality risk in individuals aged ≥55, depending on gender.
Material and methods
. The analysis included data from the prospective cohort study "Stress, Aging and Health Study in Russia" (SAHR...
A. Imaeva, N. А. Imaeva, Y. Balanova et al.· CARDIOVASCULAR THERAPY AND P...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.